Roche and FDA start negotiations on Alzheimer's disease drug candidate Gantenerumab

CompilationTom Lee

Roche is currently negotiating with the U.

According to a study published in Nature Medicine in June this year, Gantenerumab improved the levels of many biomarkers in patients with hereditary Alzheimer's disease

The DIAN-TU-001 (NCT01760005) trial compared Gantenerumab manufactured by Roche and its US subsidiary Genentech and Solanezumab manufactured by Eli Lilly against patients with rare, inherited, and early-onset Alzheimer’s The curative effect of patients

Researchers said that the patients participating in the trial are in multiple stages of asymptomatic and symptomatic diseases

Schwan revealed that Roche plans to complete Phase 3 trials of the drug in the second half of 2022

Gantenerumab is a monoclonal antibody targeting β amyloid peptide

The advocacy of the Alzheimer's disease amyloid hypothesis in the pharmaceutical industry seems to have signs of recovery, thanks to BioGen's controversial Aduhelm

Reference source: Roche engaged in talks with FDA for Alzheimer's drug candidate